Comparison tool

Vesugen vs Livagen side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

VesugenLivagen

Share this peptide comparison

Property	Vesugen	Livagen
Category	Bioregulators	Bioregulators
Also known as	Lys-Glu-Asp, KED	Lys-Glu-Asp-Ala, KEDA
FDA approved	No	No
Clinical status	Preclinical research; reported as approved in Russia as a supplement Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical research; reported as approved in Russia as a supplement Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Vascular health, blood vessel support, circulation	Gene expression, cellular aging, liver health
How it works	Vesugen is described as KED, a short cytogen-class peptide. The proposed mechanism in the supplied source is an epigenetic gene-expression model from the Khavinson group: KED is hypothesized to interact with promoter regions and affect expression patterns involving genes such as CASP3, APOE, GAP43, and SOD2. The source frames this as supported by in-vitro and molecular-docking work, not as a broadly established receptor-mediated mechanism or clinical consensus.	Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.
Typical dosing	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual
Research dosing	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typical duration	10-30 day cycles	10-30 day cycles
Administration	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning, empty stomach Empty stomach	Morning on an empty stomach Take on an empty stomach
Evidence level	Preclinical	Preclinical
Possible side effects	Generally well tolerated (Source-reported tolerability statement; detailed safety data are not provided in the supplied evidence.) Limited safety data outside Russia (The source flags limited external safety evidence, so safety conclusions remain uncertain.) Not FDA approved (Regulatory status note from the source; not a physiological side effect.)	Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.) Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.) Not FDA approved (This is regulatory status, not an adverse effect.)
Research summary	The supplied research summary emphasizes non-human evidence. It reports data from a 5xFAD transgenic Alzheimer's mouse model in which KED was associated with mushroom dendritic spine density moving toward control values after intraperitoneal dosing at 400 micrograms per kg, with related hippocampal cell-culture findings. For vascular claims, the source points mainly to Russian in-vitro and observational material and states that registered human trials have not confirmed those effects. Vascular efficacy should therefore be treated as preliminary based on the provided evidence.	The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.
References	PubMed Central PubMed Central	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Vesugen

Livagen

Category

Bioregulators

Also known as

Lys-Glu-Asp, KED

Lys-Glu-Asp-Ala, KEDA

FDA approved

Clinical status

Preclinical research; reported as approved in Russia as a supplement

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical research; reported as approved in Russia as a supplement

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Vascular health, blood vessel support, circulation

Gene expression, cellular aging, liver health

How it works

Vesugen is described as KED, a short cytogen-class peptide. The proposed mechanism in the supplied source is an epigenetic gene-expression model from the Khavinson group: KED is hypothesized to interact with promoter regions and affect expression patterns involving genes such as CASP3, APOE, GAP43, and SOD2. The source frames this as supported by in-vitro and molecular-docking work, not as a broadly established receptor-mediated mechanism or clinical consensus.

Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

Typical dosing

10-20 mg daily · Once or twice daily

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual

Research dosing

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typical duration

10-30 day cycles

Administration

Oral capsules or sublingual

Timing

Morning, empty stomach

Empty stomach

Morning on an empty stomach

Take on an empty stomach

Evidence level

Preclinical

Possible side effects

Generally well tolerated (Source-reported tolerability statement; detailed safety data are not provided in the supplied evidence.)
Limited safety data outside Russia (The source flags limited external safety evidence, so safety conclusions remain uncertain.)
Not FDA approved (Regulatory status note from the source; not a physiological side effect.)

Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.)
Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.)
Not FDA approved (This is regulatory status, not an adverse effect.)

Research summary

The supplied research summary emphasizes non-human evidence. It reports data from a 5xFAD transgenic Alzheimer's mouse model in which KED was associated with mushroom dendritic spine density moving toward control values after intraperitoneal dosing at 400 micrograms per kg, with related hippocampal cell-culture findings. For vascular claims, the source points mainly to Russian in-vitro and observational material and states that registered human trials have not confirmed those effects. Vascular efficacy should therefore be treated as preliminary based on the provided evidence.

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

References

PubMed Central PubMed Central

Source Source

+2 more

Source Source

Full profile

View Details